YOLFTbeta
Xinxiang Tuoxin Pharmaceutical Co.Ltd.

Xinxiang Tuoxin Pharmaceutical Co.Ltd.

301089 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

20.55CNY-0.47 (-2.24%)

Price History

Full chart

Market Stats

Previous Close21.02
Open21.00
Day Range20.39 – 21.05
52-Week Range19.33 – 36.34
Volume1.28M
Market Cap3.10B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.63
Dividend Yield0.00%
Beta-0.61
50-Day Avg23.50
200-Day Avg26.05

About

Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxiang, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Shaohua Yang
  • Employees1.54K
  • HeadquartersNo. 515, Kelong Avenue, High-tech Zone, Xinxiang, China, 453000, China
  • Websitehttps://www.tuoxinpharm.com

Leadership

  • Mr. Shaohua YangGM & Non-Independent Director · b. 1994
  • Ms. Huijuan JiaoChief Financial Officer · b. 1966
  • Mr. Xiuqiang WangDeputy GM & Director · b. 1970
  • Ms. Yuhua YangBoard Secretary · b. 1990
  • Mr. Tao LiDeputy General Manager · b. 1981
  • Zhen Wei YuAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue385.96M527.94M502.48M784.72M835.51M421.69M378.34M
Growth (%)-+36.79%-4.82%+56.17%+6.47%-49.53%-10.28%
Cost of Revenue227.07M303.03M311.96M313.00M351.95M295.75M278.55M
Gross Profit158.89M224.91M190.52M471.73M483.56M125.95M99.80M
Gross Margin41.17%42.60%37.92%60.11%57.88%29.87%26.38%
Operating Expense76.35M73.95M100.04M146.60M157.10M139.86M147.44M
Operating Income82.54M150.96M90.48M325.12M326.46M-13.91M-47.65M
Operating Margin21.39%28.59%18.01%41.43%39.07%-3.30%-12.59%
EBITDA159.50M194.83M118.13M369.17M363.46M20.03M-5.96M
EBITDA Margin41.32%36.90%23.51%47.05%43.50%4.75%-1.58%
Net Income61.25M112.80M65.71M286.54M243.07M-19.88M-69.66M
Net Income Margin15.87%21.37%13.08%36.51%29.09%-4.72%-18.41%
R&D15.52M18.82M20.97M31.02M51.25M40.05M42.68M
R&D as % of Total Revenue4.02%3.57%4.17%3.95%6.13%9.50%11.28%
Interest Expense64.71M13.87M9.13M3.38M337.07K53.52K151.04K
Interest Expense % of Total Revenue16.77%2.63%1.82%0.43%0.04%0.01%0.04%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets739.85M946.48M1.39B1.84B1.84B1.76B1.67B
Total Liabilities356.74M455.61M296.35M466.89M235.72M205.72M181.12M
Total Equity383.11M490.87M1.10B1.38B1.60B1.55B1.48B
Cash103.76M158.22M284.20M307.09M148.55M69.23M140.26M
Net Debt29.31M------

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow86.38M120.00M58.19M268.85M26.95M102.67M-26.19M
Capital Expenditure76.20M74.12M112.73M148.33M185.22M83.91M44.45M
Free Cash Flow10.17M45.88M-54.53M120.52M-158.27M18.76M-70.64M
Dividends Paid13.99M9.60M7.92M14.98M50.67M31.64M-
FCF to OCF11.78%38.23%-93.71%44.83%-587.19%18.27%269.76%
Dividend Paid to FCF137.50%20.93%-14.52%12.43%-32.02%168.67%-

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual0.230.200.441.412.420.040.03-0.550.02-0.03-0.01-0.14-0.03-0.12-0.09-0.31-0.08-0.14
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap3.10B
Enterprise Value2.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.60
Price / Book2.10
EPS-0.63
Book Value11.52
Revenue (TTM)407.75M
Gross Profit (TTM)67.27M
EBITDA-13.53M
Profit Margin-19.46%
Operating Margin-18.68%
Return on Equity-5.30%
Return on Assets-3.45%
Shares Outstanding126.54M
Shares Float59.35M
Beta-0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.25May 23, 2024
20231×
0.40Jun 6, 2023
20221×
0.10May 25, 2022